Capital RequirementsThe company noted it would need to raise significant dilutive capital to support such studies, which may not make the most strategic sense at this stage.
Financial PerformanceThese Phase 3 studies would require significant capital to run, which we estimate could cost ~$150-200M.
Strategic ConcernsThe company noted it would need to raise significant dilutive capital to support such studies, which may not make the most strategic sense at this stage.